Edwards Lifesciences’ Unifying Generations Report Seeks to Transform Perceptions of the “Pivotal” 3rd Generation
21.6.2022 11:00:00 EEST | Business Wire | Press release
Edwards Lifesciences today published ‘Unifying Generations: Building the Pathway to Intergenerational Solidarity’ – a report, based on a survey of 12,850 Europeans across generations, that demonstrates the need to change perceptions of the value of people aged over-65 and their cohesion with younger generations.
“The European population is ageing. By 2040, 155 million people are expected to be over 65 1 . This demographic change is often referred to as a challenge, which gives a misleading and negative impression of the contributions of over-65s to the society,” commented Jean-Luc Lemercier, Corporate Vice President, EMEA, Canada and Latin America, Edwards Lifesciences. “The survey results demonstrate that the senior population, and especially the pivotal 3rd generation, is an active, committed and engaged contributor to cohesion within families and the community.”
To provide insights on the role of the senior population in society and the benefits of intergenerational interactions, Edwards Lifesciences joined forces with experts to conduct a survey examining the perceptions and experience of intergenerational solidarity of 12,850 citizens across 6 European countries (France, Germany, Ireland, Italy, Spain, and the UK). The results formed the basis of the newly available Unifying Generations report.
In contrast to existing perceptions, the survey results highlighted the significant social contributions of the 3rd generation. They contribute to their families and communities, through volunteering (19%) and providing care to others (24%).2 Seventy-one percent (71%) of over-65s also provide significant financial support to younger people.2 Younger generation respondents stated how important they felt the support the older generation provided was in their day-to-day lives, with 83% stating it was very important or somewhat important.2
“The Unifying Generations Survey gives an accurate picture of the current situation of intergenerational solidarity in several European countries. The results of this survey show a strong desire for more intergenerational interactions from both younger and older generations. The survey also presents the great value of listening, mentoring and coaching; contributing to community well-being through volunteering; sharing knowledge of new technology and digital skills; and many other ways of encouraging cooperation in a society for all ages. The survey data is a useful reference document that will encourage social organisations to promote intergenerational solidarity programs at local, national and international levels in European countries,” commented Mr. Angel Yagüe Criado, Project Manager, The Spanish Confederation of Older People’s Association (CEOMA).
Results showed that the pandemic seems to have had a negative impact on intergenerational interaction, with 40% of respondents saying they spend less time with different generations since the pandemic.2 However, one of the most positive themes that emerged from the report was the willingness to improve intergenerational interactions. Respondents were 11 times more likely to think closer relations between different generations are a good thing (77%) vs. a bad thing (7%). 2 In fact, 92% of survey respondents confirmed they were open to having a friend from a different generation.
“The study suggests that extremely positive and varied intergenerational interactions are present in society and also valued by all age groups. It’s important that policies and strategies are developed that help maintain and strengthen these relations going forward,” said Prof George W Leeson, Professorial Fellow, Oxford Institute of Population Ageing, University of Oxford.
A number of different benefits of improving intergenerational interactions were also highlighted. The most important benefits identified were companionship or friendship (20%) and mental and emotional wellbeing (19%). Additionally, 23% of younger respondents believe that mentoring or educational schemes provided by national or local government would help them to do more with older generations.2
The report recommends three actions that can be considered as a result of the survey findings. They are: a campaign to transform perceptions of the value of senior people and their interactions with younger generations, greater opportunities for mentoring and knowledge sharing from older to younger generations; and schemes that help senior people interact more digitally.
“Recognising and celebrating the knowledge, skills, and experiences of senior people is at the heart of the report and of promoting intergenerational solidarity,” added Jean-Luc Lemercier. “As we build back after the pandemic, we should change perceptions of the value our senior populations – particularly the pivotal 3rd generation – provide to society and the importance of protecting their health and well-being.”
To learn more and download the full report please visit https://www.edwards.com/ch-en/aboutus/unifying-generations/.
About Edwards Lifesciences
Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on LinkedIn and Twitter.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
About Unifying Generations
Unifying Generations is an initiative that springs from the company’s commitment to the patients it serves and illustrates the aspiration to create a community unified in its mission to improve the quality of life around the world.
###
1 Eurostat (2017) People in the EU – population projections, http://ec.europa.eu/eurostat/statistics-explained/index.php?-title=People_in_the_EU_-_population_projections
2 Censuswide. Unifying Generations. A survey of over 12,850 people in Europe. Survey carried out 04/04/2022 – 14/04/2022. Data on file. Survey funded by Edwards Lifesciences.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005242/en/
Contact information
Media contacts:
Julie Tracol
julie_tracol@edwards.com
+41 (0)75 431 74 95
Michael George
Michael_George@edwards.com
+41 79 487 71 47
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
